Paediatric pharmacovigilance in clinical research and drug development

Guide to Paediatric Drug Development and Clinical Research

Volumn , Issue , 2010, Pages 131-137

  Mentzer, Dirk ^a   Day, Simon ^b  

^a PAUL EHRLICH INSTITUT   (Germany)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864309567     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/B978-380559363-2.31558-2     Document Type: Chapter

References (19)

1. Kimland E, Bergman U, Lindemalm S, Bottiger Y: Drug related problems and off-label drug treatment in children as seen at a drug information centre. Eur J Pediatr 2006;166:527-532.
2. Hartford CG, Petchel KS, Mickail H, Perez-Gutthann S, McHale M, Grana JM, Marquez P: Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMA/CHMP risk-management guidelines. Drug Saf 2006;29:657-673.
3. International Conference on Harmonisation (ICH), 2000: Topic E 11: Clinical Investigation of Medicinal Products in the Paediatric Population. http://www.europa.ema.eu./pdfs/human/ich/271199EN.pdf
4. Nunn T, Williams J: Formulation of medicines for children. Br J Clin Pharmacol 2005;59:674-676.
5. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-1167.
6. World Health Organization Guideline published in 2007, Promoting safety of medicines for children. www.who.int/medicines/publications/essentialmedi-cines/Promotion_safe_med_childrens.pdf
7. Turner S, Nunn AJ, Fielding K, Choonara I: Adverse drug reactions to unlicensed and off label drugs on paediatric wards: a prospective study. Acta Paediatr 1999;88:965-968.
8. Hören B, Montastruc JL, LapeyreMestre M: Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002;54:665-670.
9. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 27 December 2006 on medicinal products for paediatric use. http://www.ema.europa.eu/htms/human/paediatrics/regulation.htm.
10. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M: Incidence of adverse drug reactions in paediatric in/outpatients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001;52:77-83.
11. Haffner S, von Laue N, Wirth S, Thür-mann PA: Detecting adverse drug reactions on paediatric wards: intensified surveillance versus computerised screening of laboratory values. Drug Saf 2005;28:453-464.
12. Neubert A, Dormann H, Weiss J, et al: Are computerised monitoring systems of value to improve pharmacovigilance in paediatric patients? Eur J Clin Pharmacol 2006;62:959-965.
13. Guideline on the need for non-clinical testing in juvenile animals of pharma-ceuticals for paediatric indication (EMA/CHMP/SWP/169215/2005), published 24.01.2008.
14. Wong I, Murray ML: The potential of UK clinical databases in enhancing pae-diatric medication research. Br J Clin Pharmacol 2005;59:750-755.
15. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW: Principles of signal detection in pharma-covigilance. Drug Saf 1997;16:355-365.
16. Garcia Rodriguez LA, Perez Gutthann S: Use of the UK General Practice Research Database for Pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425.
17. Bate A, Lindquist M, Edwards IR: A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacology 1998;54:315-321
18. Evans SJW, Waller PC, Davis S: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharma-coepidemiol Drug Saf 2001;10:483-486.
19. Evans SJW: Stratification for spontaneous report databases. Drug Saf 2008; 31:1049-1053.